NGL Fine Chem's Financial Report Shows Mixed Results for Q1 FY25

NGL Fine Chem, a smallcap pharmaceutical company, recently announced its financial results for the quarter ending June 2024. The company’s stock has been given a ‘Hold’ call by MarketsMOJO.

According to the financial report, NGL Fine Chem’s Profit After Tax (PAT) for the half-yearly period has shown a growth of 20.81% year on year, indicating a positive trend in the near term. The company’s Net Sales for the quarter have also increased by 27.74% year on year, showing a positive sales trend in the near term.

However, there are some areas of concern for NGL Fine Chem. The company’s Operating Cash Flow for the year has been the lowest in the last three years, indicating a decline in cash revenues from business operations. The Operating Profit (PBDIT) for the quarter has also been the lowest in the last five quarters, with a negative trend in the near term. The Operating Profit Margin for the quarter has also decreased, showing a deterioration in the company’s efficiency.

Moreover, the Profit Before Tax less Other Income (PBT) for the quarter has been the lowest in the last five quarters, with a negative trend in the near term. The company’s Non Operating Income for the quarter is also high, accounting for 49.87% of the Profit Before Tax (PBT). This indicates that the company’s income from non-business activities is not sustainable in the long run.

Additionally, NGL Fine Chem’s Debtors Turnover Ratio for the half-yearly period has been the lowest in the last five periods, indicating a slower pace in settling its debtors. The company’s Non Operating Income for the quarter has also been the highest in the last five quarters, which may not be sustainable in the long run.

Overall, NGL Fine Chem’s financial performance for the quarter ending June 2024 has been flat, with some positive and negative trends. Investors are advised to hold their position in the company’s stock and keep a close eye on its future financial reports.